Safety and Tolerance of a Nutritional Intervention Program- In.Form 1.2

Nature's Sunshine Products

Status: Completed

Conditions: Obesity

Treatments: Other: PROG2

Study type: Interventional

Funder types: Industry

Identifiers

NCT03098056

NSP-CT-010

Details and patient eligibility

About

The study evaluated and the safety, tolerance and acceptability of a lifestyle modification program with nutritional supplementation in generally healthy overweight subjects with cardiometabolic risk factors. Experience will be compared to a historical controls.

Full description

To investigate the safety, tolerance and acceptability of a low-glycemic load diet combined with exercise and lifestyle modification education and a meal replacement formula and targeted nutraceuticals (PROG 2) in generally healthy, overweight subjects, fifty subjects with two or more cardiometabolic risk factors, aged 18 to 69 will be randomized into different arms, 13-week intervention trial. To evaluate safety and tolerability, questionnaires were collected weekly. Additionally, baseline, week 9 and 13 fasting blood samples will be drawn for blood counts, metabolic profiles, plasma lipids, and additional cardiovascular risk factors. Vitals signs, weight and body composition were monitored weekly.

Enrollment: 50 patients

Sex: All

Ages: 18 to 69 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

Generally healthy subjects (men and women ≥ 18 and ≤ 69 years old) were required:

• to be overweight or obese (BMI ≥ 27 kg/m2 and ≤ 50 kg/m2),
• to exhibit visceral obesity (waist circumference ≥ 35 inches for women and ≥ 39 inches for men),
• and demonstrate signs of cardiometabolic dysfunction. Specifically, subjects were required to have:
• elevated LDL cholesterol ≥ 130 mg/dl
• and/or elevated TG defined as TG ≥ 130 mg/dl. Additionally, subjects were required to have at least one of the following criteria (unless subject had both elevated LDL and TG):
• HDL < 50 mg/dl for women and < 40 mg/dl for men,
• blood glucose ≥ 100 mg/dl, HbA1C ≥ 5.7%,
• or Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) score defined as ≥ 2.0.

Exclusion Criteria included:

• Pregnancy
• Lactation
• Recent changes in prescription medications, over-the-counter medications, medical foods, and nutritional supplements
• Recent or regular use of narcotics, investigational drugs, corticosteroids, anticoagulants, neuroactive medications, or medication or supplements relevant to hyperglycemia or hyperlipidemia
• Chronic use of over-the-counter medication which would interfere with study endpoints including NSAIDS, laxatives and antacids
• Allergy or intolerance to study products
• Serious, unstable medical conditions including known infection with HIV, tuberculosis or hepatitis; cardiovascular disease; Diabetes Mellitus; autoimmune diseases; malignancy; psychiatric disease; substance abuse;
• Abnormal laboratory findings
• Participating in or planning to begin a weight loss diet during the study period
• Difficulty in swallowing pills
• Lifestyle or schedule incompatible with the study protocol.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

50 participants in 1 patient group

PROG2

Experimental group

Description:

All subjects will be participating in a lifestyle change program - specifically a high protein, limited carbohydrate food plan (High Phyto-PRO food plan), physical activity and a cognitive behavioral program consisting of 11 group visit. Participants will be recieving nutritional Supplements.

Treatment:

Other: PROG2